A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
Risk of serotonin syndrome in acutely ill patients receiving linezolid and opioids concomitantly: A retrospective cohort study
[post]
2022
unpublished
Introduction: Linezolid is an oxazolidinone antibiotic with a reversible, non-selective monoamine oxidase inhibitory effect. Combining linezolid with serotonergic agents may increase serotonin syndrome (SS) risk. Secondary to its high tissue penetration, linezolid is recommended in patients with suspected or confirmed resistant gram-positive bacterial infections, as pneumonia, and skin-soft tissue infections, especially if vancomycin cannot be used. However, it is unclear whether
doi:10.21203/rs.3.rs-1431032/v1
fatcat:vkfinqrzxvdvxaawhrt7qrbztq